BE899271A - Medicament contenant de la 2,6-bis-diethanolamino-4, 8-dipiperidino-pyrimido /5,4-d/-pyrimidine augmentant le taux des lipoproteines de haute densite atheroprotectrice. - Google Patents

Medicament contenant de la 2,6-bis-diethanolamino-4, 8-dipiperidino-pyrimido /5,4-d/-pyrimidine augmentant le taux des lipoproteines de haute densite atheroprotectrice.

Info

Publication number
BE899271A
BE899271A BE0/212648A BE212648A BE899271A BE 899271 A BE899271 A BE 899271A BE 0/212648 A BE0/212648 A BE 0/212648A BE 212648 A BE212648 A BE 212648A BE 899271 A BE899271 A BE 899271A
Authority
BE
Belgium
Prior art keywords
pyrimidine
bis
high density
atheroprotector
dipiperidino
Prior art date
Application number
BE0/212648A
Other languages
English (en)
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of BE899271A publication Critical patent/BE899271A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Médicament augmentant le taux des lipoprotéines de haute densité, qui contient de la 2,6-bis-di-éthanolamino-4,8-dipipéridinopyrimido(5,4-d)-pyrimidine ou un de ses sels d'addition d'acides physiologiquement acceptables et un ou plusieurs excipients inertes. La dose unitaire du médicament est de 50 à 150 mg et, de préférence, de 80 à 100 mg. Le principe actif étant pratiquement atoxique, le nouveau médicament est toléré à peu près sans effets secondaires.
BE0/212648A 1983-03-29 1984-03-28 Medicament contenant de la 2,6-bis-diethanolamino-4, 8-dipiperidino-pyrimido /5,4-d/-pyrimidine augmentant le taux des lipoproteines de haute densite atheroprotectrice. BE899271A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833311355 DE3311355A1 (de) 1983-03-29 1983-03-29 Arzneimittel mit einer die atheroprotektiven high density lipoproteine steigernden wirkung, enthaltend 2,6-bis-diaethanolamino-4,8-dipiperidino-pyrimido (5,4-d)-pyrimidin

Publications (1)

Publication Number Publication Date
BE899271A true BE899271A (fr) 1984-09-28

Family

ID=6194954

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/212648A BE899271A (fr) 1983-03-29 1984-03-28 Medicament contenant de la 2,6-bis-diethanolamino-4, 8-dipiperidino-pyrimido /5,4-d/-pyrimidine augmentant le taux des lipoproteines de haute densite atheroprotectrice.

Country Status (8)

Country Link
EP (1) EP0123841B1 (fr)
JP (1) JPS59184126A (fr)
AU (1) AU565857B2 (fr)
BE (1) BE899271A (fr)
DE (2) DE3311355A1 (fr)
DK (1) DK163031C (fr)
IT (1) IT1199077B (fr)
ZA (1) ZA842286B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT393962B (de) * 1987-10-22 1992-01-10 Thomae Gmbh Dr K Synergistische arzneimittelkombination mit einem gehalt an einem phosphodiesterase-hemmer und derenverwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51136696A (en) * 1975-05-16 1976-11-26 Otsuka Pharmaceut Co Ltd Process for preparing aikylamino-substituted pyrimidopyrimidine deriva tives

Also Published As

Publication number Publication date
DK67184D0 (da) 1984-02-14
IT8447781A0 (it) 1984-03-01
IT1199077B (it) 1988-12-30
ZA842286B (en) 1985-12-24
DE3479786D1 (en) 1989-10-26
DE3311355A1 (de) 1984-10-04
DK163031C (da) 1992-06-09
EP0123841A1 (fr) 1984-11-07
AU2617884A (en) 1984-10-04
EP0123841B1 (fr) 1989-09-20
JPS59184126A (ja) 1984-10-19
DK67184A (da) 1984-09-30
AU565857B2 (en) 1987-10-01
DK163031B (da) 1992-01-13

Similar Documents

Publication Publication Date Title
DE69206345D1 (de) Arzneimittel zur intranasalen Verabreichung, die Ketorolac R enthalten.
ATE522211T1 (de) Stabilisierte fibrat-mikropartikel
CY1112861T1 (el) Χρηση παραγωγων οξικου (-) (3-τριαλομεθυλοφαινοξυ) (4-αλοφαινυλ) οξεος για τη θεραπεια της υπερουρικαιμιας
RU97103563A (ru) Композиции длительного высвобождения венлафаксин гидрохлорида, композиция пленочного покрытия, способ обеспечения терапевтически активной концентрации венлафаксина и способ исключения нулевых и пиковых концентраций лекарственного средства
DE69329400D1 (de) L-Dopa Ester enthaltende Zusammensetzung
DK0724885T3 (da) Pernasal sammensætning og pernasalt præparat indeholdende dette
US4777047A (en) Transdermal application form of calcium antagonists
RU2039556C1 (ru) Фармацевтическая композиция противоалкогольного, стимулирующего энергетический обмен, кислотообразующую и секреторную функцию слизистой желудка, радиопротекторного и противохолерного действия, способ профилактики и лечения алкогольного опьянения и алкогольного абстинентного синдрома, способ стимуляции энергетического обмена, способ стимуляции и диагностики кислотообразующей и секреторной функции слизистой желудка и способ защиты от радиационного поражения теплокровных животных
RU96109699A (ru) Гуанидиды алкенилкарбоновых кислот, способ их получения, содержащее их лекарственное или диагностическое средство, способ его получения, способ лечения и профилактики сердечных заболеваний
Mann et al. Calcium antagonists in the treatment of sudden deafness
SU1545941A3 (ru) Способ получени оксотиазолидиновых соединений
BE899271A (fr) Medicament contenant de la 2,6-bis-diethanolamino-4, 8-dipiperidino-pyrimido /5,4-d/-pyrimidine augmentant le taux des lipoproteines de haute densite atheroprotectrice.
DE69131553T2 (de) Arzneimittel enthaltend Mischungen von höheren primären aliphatischen Alkoholen zur Behandlung von Hypercholesterolämie und Hyperlipoproteinämie Typ II und zur Stimulation des sexuellen Verhaltens bei Tieren und Menschen
ES2050653T3 (es) Tableta de granulos multiples, de emision sostenida.
ATE8739T1 (de) Pharmazeutische zubereitungen.
JPS5551019A (en) Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof
KR880004810A (ko) 소화성 궤양 치료제
CA2069313A1 (fr) Inhibiteurs de la biosynthese de la pyrimidine utiles commes agents immunosuppresseurs
US3761594A (en) Composition for control of coccidiosis containing a coccidiostiatically active 4-hydroxy-quinoline and meticlorpindol
KR880003973A (ko) 약리적 활성 화합물 및 용도
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
FR2547730B1 (fr) Medicament hypolipidemiant contenant comme ingredient actif la d-3-acetoxy-cis-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(p-methoxyphenyl)-1,5-benzothiazepine-4(5h)-one ou un de ses sels d'addition d'acides acceptables en pharmacie
Swanson et al. The pharmacology and toxicology of ‘Valmid’(ethinamate, Lilly)
KR890004691B1 (ko) 만성 폐색성 폐질환의 치료용 및 조성물
FR2344545A1 (fr) Amides d'acides (2-pyrimidinylthio)-alcanoiques ayant une activite antilipemique, procedes pour leur preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: DR. KARL THOMAE G.M.B.H.

Effective date: 19930331